The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

被引:11
作者
He, Yanxia [1 ,2 ]
Gao, Yan [1 ,2 ]
Ping, Liqin [1 ,2 ]
He, Haixia [3 ]
Huang, Cheng [1 ,2 ]
Bai, Bing [1 ,2 ]
Wang, Xiaoxiao [1 ,2 ]
Li, Zhiming [1 ,2 ]
Cai, Qingqing [1 ,2 ]
Huang, Yuhua [1 ,4 ]
Pan, Xueyi [5 ]
Zeng, Wenbin [5 ]
Liu, Yanan [5 ]
Huang, Huiqiang [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou, Peoples R China
[5] Guangdong Pharmaceut Univ, Dept Hematol, Affiliated Hosp 1, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Hemophagocytic lymphohistiocytosis; Extranodal NK; T-cell lymphoma; Anti-PD-1; antibody; Epstein-Barr virus; T-CELLS; PEMBROLIZUMAB; NASAL;
D O I
10.1007/s00432-022-04147-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Anti-PD-1 antibody (anti-PD-1 mAb) showed favorable outcomes in some patients with relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL). However, the role of anti-PD-1 antibody in NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis (NK/T-LAHS) remains unclear. Here, we evaluated the efficacy and toxicity of anti-PD-1 antibody-based treatment in NK/T-LAHS patients. Methods The clinical data of 98 patients diagnosed with NK/T-LAHS at Sun Yat-sen University Cancer Center and the First Affiliated Hospital of Guangdong Pharmaceutical University from May 2014 to November 2021 were retrospectively analyzed. All patients received anti-HLH [HLH-2004 (etoposide, dexamethasone, cyclosporine A) or DEP-based (liposomal doxorubicin, etoposide, methylprednisolone)] regimen and sequential anti-ENKTL chemotherapy (ChT) combined with anti-PD-1 antibody or not. Results The overall response rate (ORR) of the anti-PD-1 mAb plus ChT regimens was higher than that of the ChT regimens (73.3% vs. 45.5%, P = 0.041). The toxicity of the anti-PD-1 mAb plus ChT regimens was tolerable. Except for higher rate of neutropenia, no significant difference in adverse events (AEs) was observed between the two groups. When the optimal response to anti-ENKTL was achieved, the median EBV DNA levels in patients who received anti-PD-1 mAb plus ChT were significantly lower than patients who received ChT only (878 copies/mL vs. 18,600 copies/mL, P = 0.001). With a median follow-up of 26.6 months (range 0-65.9 months), the median overall survival (mOS) was 3.5 months (95% CI:2.3-4.7 months). Patients treated with anti-PD-1 mAb plus ChT experienced a longer mOS than those who received ChT only [5.2 months (95% CI: 2.5-7.8 months) vs. 1.5 months (95% CI: 0.5-2.6 months), P = 0.002]. Cox multivariate analysis found that anti-PD-1 mAb was an independent prognostic factor for all NK/T-LAHS patients. Conclusion In conclusion, anti-PD-1 mAb combined with ChT regimens seemed to be associated with prolonged survival in NK/T-LAHS patients and may represent a potentially promising treatment strategy for this population.
引用
收藏
页码:2017 / 2027
页数:11
相关论文
共 37 条
[1]   Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].
Altorki, Nasser K. ;
McGraw, Timothy E. ;
Borczuk, Alain C. ;
Saxena, Ashish ;
Port, Jeffrey L. ;
Stiles, Brendon M. ;
Lee, Benjamin E. ;
Sanfilippo, Nicholas J. ;
Scheff, Ronald J. ;
Pua, Bradley B. ;
Gruden, James F. ;
Christos, Paul J. ;
Spinelli, Cathy ;
Gakuria, Joyce ;
Uppal, Manik ;
Binder, Bhavneet ;
Elemento, Olivier ;
Ballman, Karla, V ;
Formenti, Silvia C. .
LANCET ONCOLOGY, 2021, 22 (06) :824-835
[2]   Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project [J].
Au, Wing-yan ;
Weisenburger, Dennis D. ;
Intragumtornchai, Tanin ;
Nakamura, Shigeo ;
Kim, Won-Seog ;
Sng, Ivy ;
Vose, Julie ;
Armitage, James O. ;
Liang, Raymond .
BLOOD, 2009, 113 (17) :3931-3937
[3]   Restoring function in exhausted CD8 T cells during chronic viral infection [J].
Barber, DL ;
Wherry, EJ ;
Masopust, D ;
Zhu, BG ;
Allison, JP ;
Sharpe, AH ;
Freeman, GJ ;
Ahmed, R .
NATURE, 2006, 439 (7077) :682-687
[4]   Hemophagocytic lymphohistiocytosis in adults [J].
Bhatt, Neel S. ;
Oshrine, Benjamin ;
An Talano, Julie .
LEUKEMIA & LYMPHOMA, 2019, 60 (01) :19-28
[5]   PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [J].
Bi, Xi-wen ;
Wang, Hua ;
Zhang, Wen-wen ;
Wang, Jing-hua ;
Liu, Wen-jian ;
Xia, Zhong-jun ;
Huang, Hui-qiang ;
Jiang, Wen-qi ;
Zhang, Yu-jing ;
Wang, Liang .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[6]   Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma [J].
Cai, Jun ;
Liu, Panpan ;
Huang, Huiqiang ;
Li, Yajun ;
Ma, Shuyun ;
Zhou, Hui ;
Tian, Xiaopeng ;
Zhang, Yuchen ;
Gao, Yan ;
Xia, Yi ;
Zhang, Xuanye ;
Yang, Hang ;
Li, Lirong ;
Cai, Qingqing .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
[7]  
Carlino MS, 2021, LANCET, V398, P1002, DOI 10.1016/S0140-6736(21)01206-X
[8]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[9]   Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma:: Nuclear factor-κB pathway as a potential therapeutic target [J].
Chuang, Huai-Chia ;
Lay, Jong-Ding ;
Hsieh, Wen-Chuan ;
Su, Ih-Jen .
CANCER SCIENCE, 2007, 98 (09) :1281-1287
[10]   Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL [J].
Ding, Wei ;
LaPlant, Betsy R. ;
Call, Timothy G. ;
Parikh, Sameer A. ;
Leis, Jose F. ;
He, Rong ;
Shanafelt, Tait D. ;
Sinha, Sutapa ;
Le-Rademacher, Jennifer ;
Feldman, Andrew L. ;
Habermann, Thomas M. ;
Witzig, Thomas E. ;
Wiseman, Gregory A. ;
Lin, Yi ;
Asmus, Erik ;
Nowakowski, Grzegorz S. ;
Conte, Michael J. ;
Bowen, Deborah A. ;
Aitken, Casey N. ;
Van Dyke, Daniel L. ;
Greipp, Patricia T. ;
Liu, Xin ;
Wu, Xiaosheng ;
Zhang, Henan ;
Secreto, Charla R. ;
Tian, Shulan ;
Braggio, Esteban ;
Wellik, Linda E. ;
Micallef, Ivana ;
Viswanatha, David S. ;
Yan, Huihuang ;
Chanan-Khan, Asher A. ;
Kay, Neil E. ;
Dong, Haidong ;
Ansell, Stephen M. .
BLOOD, 2017, 129 (26) :3419-3427